14 October 2023 : Clinical Research
Influence of Age, Gender, Frailty, and Body Mass Index on Serum IL-17A Levels in Mature Type 2 Diabetic Patients
Zvonimir Bosnić1ABEF, František Babič
2CDEG*, Thomas Wittlinger34DEG, Viera Anderková2C, Ines Šahinović 5B, Ljiljana Trtica Majnarić16ABDEF
DOI: 10.12659/MSM.940128
Med Sci Monit 2023; 29:e940128
Table 1B Participant characteristics (categorical variables).
| Patient characteristics | Absolute No. |
|---|---|
| Age (years) | 50–65 – 7966–75 – 63>75 – 28 |
| Sex (M, W) | M – 75F – 95 |
| Diabetes duration (years) | <5 – 74<6, 10> – 38>10 – 58 |
| Hypertension duration (years) | <5 – 74< 6, 10> – 49>10 – 63 |
| BMI (kg/m) | <25 – 5825–30 – 67>30 – 83 |
| Nutritional status (MNA-test screening score) | Normal nutrition – 144At risk for malnutrition – 26 |
| Smoking habit | Never – 68Current – 31Ex – 71 |
| Frailty index (0 – robust; 1 – prefrail; 2 – frail) | 0 – 971 – 422 – 31 |
| Metabolic syndrome (M) = yesMetabolic syndrome (F) = yes | 74.7%96.8% |
| No. of comorbidities | ≤3 – 8>3 – 162 |
| Hypertension = yes | 89.4% |
| Cardiovascular dis. (one or more of) = yes | 51.2% |
| Coronary artery dis. = yes | 34.7% |
| Chronic heart dis. = yes | 48.8% |
| Diabetic retinopathy = yes | 28.2% |
| Chronic respiratory dis. (Chronic Obstructive Pulmonary Dis. or Asthma) = yes | 8.2% |
| Gastrointestinal dis. = yes | 42.4% |
| Osteoporosis = yes | 45.9% |
| Osteoarthritis = yes | 50.6% |
| Low back pain = yes | 65.3% |
| Thyroid gland dis. = yes | 19.4% |
| Urogenital dis. = yes | 29.4% |
| Incontinentio urinae = yes | 15.3% |
| Anxious disorders = yes | 60.6% |
| Total No. of medications prescribed | ≤3 – 9>3 – 161 |
| Metformin = yes | 72.9% |
| Sulfonylureas = yes | 22.4% |
| Pioglitazone = yes | 5.9% |
| Metformin, Sulfonylureas, Pioglitazone – alltogether (Old fashioned oral antidiabetics) = yes | 84.7% |
| dipeptidyl peptidase-4 inhibitor = yes | 17.6% |
| glucagon-like peptide-1 receptor agonists = yes | 8.8% |
| sodium-glucose cotransporter 2 inhibitors = yes | 3.5% |
| DPP4inh, GLP1ra, SGLT2inh – all together (New fashioned oral antidiabetics) = yes | 30.0% |
| Insulin therapy = yes | 23.5% |
| Angiotensin converting enzyme inhibitors or Angiotensin receptor blockers = yes | 78.2% |
| Calcium channel blockers = yes | 42.4% |
| Beta-blockers = yes | 45.3% |
| Diuretics = yes | 66.5% |
| Statins = yes | 84.1% |
| Non-steroidal anti-inflammatory drugs = yes | 71.2% |